[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586163":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Study cohort",null,"Tumour specimens stored both in optimal cutting temperature compound and formalin-fixed paraffin-embedded from patients with a first diagnosis of vulvar squamous cell carcinoma. Upon sectioning, the specimens will be analysed using phosphor imaging with FAPI radiopharmaceutical.",[13],{"name":14,"affiliation":5,"role":15},"Angela Collarino, MD, PhD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","0039 06 3015 6157","angela.collarino@policlinicogemell.it",[22],{"facility":5,"status":10,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Rome","RM","00168","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],12.51133,41.89193,{"lat":32,"lon":31},[35,37],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":36},"angela.collarino@policlinicogemelli.it",{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100586163","in-vitro-study-of-18ff-fapi-74-feasibility-in-vulvar-cancer-100586163",false,"NCT06911801","In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer","FAPI_VULVA_1","Inclusion Criteria:\n\n* Patients with histologically confirmed diagnosis of invasive vulvar cancer with squamous cell histotype, both from primary tumour site and excised metastatic LNs.\n* Availability of both FFPE and OCT stored samples from each primary tumour site and (when available) from the corresponding metastatic groin lymph nodes.\n* Samples stored in sufficient quantity not to be completely exhausted by their use for this study.\n* Optimal stored sample\n* Available clinical and histopathological data\n\nExclusion Criteria:\n\n\\- Coexistence of primary tumours other than vulvar cancer","FEMALE","18 Years",{"count":50,"type":51},90,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the expression of FAP by phosphor imaging in invasive vulvar squamous cell carcinoma specimens. This in vitro study will include all consecutive tumour specimens stored both in optimal cutting temperature (OCT) compound and formalin-fixed paraffin-embedded (FFPE) from patients with a first diagnosis of vulvar squamous cell carcinoma who underwent surgery at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.",[55],"Vulvar Squamous Cell Carcinoma",[55,57,58],"FAPI","Phosphor imaging","NOT_YET_RECRUITING","2025-04-03",{"date":62,"type":63},"2025-04-04","ACTUAL",{"date":65,"type":51},"2025-04",{"date":67,"type":51},"2026-11",{"name":5,"class":6},1]